SY-006

N/A

Report date: 2026/02/05 09:55:43
NMEFirst In Class

Base Information

Drug NameSY-006
Drug Alias NameSY-006
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLeucine-rich repeat serine/threonine-protein kinase 2 inhibitors
TargetsLeucine-rich repeat serine/threonine-protein kinase 2
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwanHong KongMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesLifearc
China Registration ClassN/A

Develop Information

Active CompaniesYabao Pharmaceutical Group Co Ltd
Inactive CompaniesN/A
Active IndicationsParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A